Device Trial Radar · NCT03843320
Impact of SAVR and TAVR on Patient's Activity and Mobility
Last checked: Nov 20, 2026Latest source record: Dec 3, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Suspended
Enrollment
340
Planned (sponsor's estimate)
Start
Dec 2021
Primary completion
Dec 2023
Study completion Dec 2024
Sponsor
- Lead sponsor
- University of PadovaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Edwards Lifesciences; Ospedale San Bortolo di Vicenza; Azienda Ospedaliera di Padova
- First posted
- Feb 18, 2019
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 75 years, up to 89 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an independent, investigator-initiated, prospective multicenter observational study with restricted grant provided by Edwards Lifesciences that aims to describe baseline (preoperative) physical function and to assess and compare 6-month postoperative changes in the physical function of patients undergoing aortic stenosis (AS) treatment with either transcatheter aortic valve replacement (TAVR) or surgical aortic valve replacement (SAVR) implanted with Edwards valve type ("SAPIEN 3" and "SAPIEN XT" for TAVR; "INSPIRIS RESILIA", "EDWARDS INTUITY" and "Carpentier-Edwards PERIMOUNT Magna-Ease" for SAVR). Secondary objectives of this study are: to evaluate the validity of wearable devices in assessing physical function in such patients and subjects' compliance in wearing the device also after a very long follow-up time up to 12 months; to assess and compare 6-month postoperative changes in Health-Related Quality of Life (HRQoL), sleep quality, cognitive function of patients undergoing AS treatment with either TAVR or SAVR. Smart watch activity tracker "Vívoactive® HR" devices by "Garmin©" will be used in the study. Devices will be distributed to the patients at time of baseline assessment, along with a Bluetooth-paired smartphone provided with a prepaid data-only SIM-card and study-customised interface. Patients will be asked to wear the device 24 hours a day, 7 days a week, from the baseline assessment to the last follow-up, 12 months after baseline.
Conditions
- Aortic Valve Stenosis
Interventions
SAPIEN 3Device
Transcatheter aortic valve replacement
SAPIEN XTDevice
Transcatheter aortic valve replacement
INSPIRIS RESILIADevice
Surgical aortic valve replacement
EDWARDS INTUITYDevice
Surgical aortic valve replacement
Carpentier-Edwards PERIMOUNT Magna-EaseDevice
Surgical aortic valve replacement
Primary outcomes
What the sponsor says the trial is designed to measure.
- 6-minute walk test (6 MWT) at 1 monthTime frame: 1 month after treatment with TAVR/SAVR
- 6-minute walk test (6 MWT) at 3 monthsTime frame: 3 months after treatment with TAVR/SAVR
- 6-minute walk test (6 MWT) at 6 monthsTime frame: 6 months after treatment with TAVR/SAVR
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Azienda Ospedaliera di Padova
Padova, PD, Italy
Azienda ULSS n.8 Berica, Vicenza - Ospedale San Bortolo
Vicenza, VI, Italy
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.